Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.00 -1.27% 156.00 155.00 157.00 156.50 156.00 156.50 60,660 09:55:24
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 280

Amryt Pharma Share Discussion Threads

Showing 4376 to 4394 of 6725 messages
Chat Pages: Latest  185  184  183  182  181  180  179  178  177  176  175  174  Older
DateSubjectAuthorDiscuss
21/2/2019
18:46
Oh thank you,we tried it along time ago on a trial for another company.
chica1
21/2/2019
18:24
AP101 is NOT a gene therapy, chica. It's just another lotion. AP101 is currently undergoing phase III trials. AMYT's very early stage gene therapy is AP103.
papillon
21/2/2019
16:45
I am only here to keep informed about the gene therapy that this company is developing. A mild form Epidermolysis Bullosa runs in my family and we have tried all lotions to no avail. Toxicity is a major factor as the immune system is weakened.The skin where you apply the ointment is generally always broken so it does enter the blood stream.
chica1
21/2/2019
13:48
mdalos - it's far more complicated than that but suffice to say liver enzyme levels were monitored very closely indeed. Am happy to discuss further but as Papillion says the best place for that would be MTFB bb.
bermudashorts
21/2/2019
13:08
Bronxville Posts: 794 Opinion: No Opinion Price: 15.55 RE: Big seller out there? Today 12:27 Are there questions on liver toxicity for AP101? Where did this come from? >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> LOL. LOL. LOL. LOL. Are you really as stupid, Bronxville, as some of your posts imply? LOL. mdalos was talking about MTFB and then, somewhat fancifully, wondered whether the same liver toxicity fears could apply to AP101 without any evidence whatsoever. MTFB's antibiotic is taken internally and there have always been fears over it's liver toxity. AP101 is a cream applied to the skin. Liver toxicity has never, ever, been a worry for AP101. You're either as thick as a two short planks conspiracy theorist, Bronxville, or you are trying to depress the AMYT share price Seeing I sold some of my shares earlier today and would like to buy them back again at a much cheaper price my message to you is keep on posting negatively on the lse asylum bb! LOL. LOL.
papillon
21/2/2019
12:52
Surely the MTFB bb is the best place to discuss MTFB mdalos? Meanwhile back to the mundane business of AMYT. Sold some shares this morning. This could easily drop back to last November's low. Who knows? The share price needs good news, but news could be a few months away when the 2018 annual results RNS is released. I'll keep my remaining shares as my core holding and will top up again when I think the share price has bottomed out.
papillon
20/2/2019
19:44
mdalos - re. Motif Bio, there is no suggestion at all that the issue was with the trial design or any failure to monitor major organs. Indeed both trials were designed following advisory meetings with the FDA. The FDA issued a CRL because they have a concern regarding liver toxicity. Iclaprim is an antibiotic that is administered intravenously to hospitalised patients with serious infections. Their organs were monitored very closely! MTFB have been so badly affected by what hopefully will be a delay in approval because they only have this one product in their pipeline and they have low cash reserves. Amryt already have a revenue generating product on the market and 3 others in their pipeline. There are always risks with any clinical trial but I would have thought last on the list would be that patients aren't monitored closely enough. Trial protocols have to be approved by both the regulators and eithics committees and also worth remembering that the AP101 trial has had an interim review by an independent DMC who have viewed unblinded data.
bermudashorts
20/2/2019
18:52
very quiet here. When should this pearl start?
ih_701710
18/2/2019
12:42
Who knows, mdalos? AP101 has already passed phase III and been APPROVED in Europe for PTW's. AP101 is a treatment applied to the skin, so is NOT a drug that is ingested by the patient. I have no idea whether MTFB's product is a skin treatment, or a drug that is ingested by the patient, but I suspect the latter. The AMYT chart doesn't look good.
papillon
17/2/2019
17:04
I totally agree, Solomon
papillon
17/2/2019
14:33
I hope he's okay. He sounded like an exceptionally decent guy.
solomon
17/2/2019
12:39
O/T greendragon777 hasn't posted on AMYT since the 4th January. In fact he hasn't posted on any ADVFN bb since 4th January. I know he was keen on cryptocurrencies. His favourite cryptocurrency, IOTA, gets a special mention in the ongoing Quadriga scandal as this BBC article shows: hTTps://www.bbc.co.uk/news/world-us-canada-47203706
papillon
14/2/2019
12:12
Bought some MTFB. Might be a bit of overreaction there. They will go back and talk to the FDA
volsung
14/2/2019
11:05
One biopharma has "tanked" today. MTFB is down an absolutely staggering 86% today!!!!
papillon
13/2/2019
22:42
radar Posts: 2,798 Opinion: No Opinion Price: 15.80 RE: Big seller out there? Mon 17:30 Looks like its going to tank soon. >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Has it tanked yet, Einstein? radar? Plonker!
papillon
12/2/2019
14:44
You could be correct, bioking. I certainly hope so. It's why I have been holding AMYT ever since it listed. It's my largest holding and I have added over the years. I'm breaking even at the current 16p share price
papillon
12/2/2019
14:15
all i can say is strong buy aggressive i think this one has even higher potential than fum .
bioking
12/2/2019
13:33
Well, chica1, the recent RNS states https://uk.advfn.com/stock-market/london/amryt-pharma-AMYT/share-news/Amryt-Pharma-PLC-EASE-Phase-III-trial-interim-effi/78992522 "Amryt will begin the recruitment process for the additional patients required and now expects a readout of the top line data from the EASE study in H2 2019." So the company states the AP101 trial results will be available in H2 2019. Whether that proves to be correct, or drags into 2020, only time will tell. 1/6/2019 to 31/12/2019 is a very wide spread. Hopefully the company is finally being cautious on timelines and the results will be available in Q3 2019 rather than Q4 2019, but who knows. You pays your money and takes your choice.
papillon
12/2/2019
12:12
Just new here..Hasn't AP101 trial results been pushed out to early 2020 as they are adding more patients?
chica1
Chat Pages: Latest  185  184  183  182  181  180  179  178  177  176  175  174  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210801 15:20:34